Overview

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.